The impact of the COVID-19 pandemic on medical education: adaptability and remote learning experience of the Peruvian American Medical Society

The COVID-19 pandemic had a significant impact on medical care and medical education in Peru. In response, the Peruvian American Medical Society (PAMS), a charitable medical organization based in the USA, pursued its medical and educational missions in Peru by adopting virtual learning technology. We developed closer collaborative relationships with several medical schools and the Peruvian Association of Medical Schools (ASPEFAM) while offering a faculty panel of twenty-four members to provide lectures and multidisciplinary webinars in Spanish. We conducted 19 webinars including COVID -19 and non-COVID-19 related topics that over the last two years attracted 14,489 participants from 23 countries. They were the foundation for twenty publications in Peruvian medical journals. Our clinical investigations competition was positively received as was our pilot project on research mentorship. The COVID -19 pandemic had a positive effect on the educational mission of PAMS in Peru.

HEPATITIS B NUCLEOCAPSID PARTICLE AS IMMUNOPOTENTIATOR OF INNATE AND ADAPTIVE IMMUNITY FOR NASAL VACCINES CIGB 2020 AND MAMBISA AGAINST COVID-19

Intro The concept of training immunity originally developed for other diseases has gained attraction during the epidemic. Several clinical trials and epidemiological analyses of populations previously immunized with BCG and other vaccines were the focus of scientific discussions. Here we show the activation of innate immunity markers both at mucosal and systemic levels with a mucosal vaccine CIGB2020 (HeberNasvacTM) containing virus-like particles (HBsAg) and nucleocapsid particle (HBcAg) of the hepatitis B virus. Moreover, the immune potentiating capacity of the HBcAg combined with RBD protein was used to formulate a specific mucosal vaccine candidate against SARS-CoV-2 (MambisaTM). Methods With CIGB 2020 (100µg HBsAg and 100 µg HBcAg) were conducted two proof of concept trials in human volunteers and a Phase I-II open, randomized, and controlled trial in 46 volunteers older than 60 years, symptomatic or close contact of COVID-19 patients. The volunteers were randomly assigned to the treatment group or not treated group. The nasal spray was administered to the treatment group on days 0, 7, and 14 together with daily sublingual administrations. Mucosal and serum samples were collected on days 0, 4, and 8. With MambisaTM vaccine (50µg RBD and 40 µg HBcAg) was conducted one proof of concept trial and a Phase I-II open and randomized trial in 1131 volunteers 19 to 60 years old, evaluating three different devices for nasal administration. All the volunteers gave written informed consent. Findings CIGB2020 activates interferon-induced genes and TLR 3, 7, and 8 at the level of oropharyngeal mucosa and PBMC. Monocyte and lymphocyte populations were also activated. One dose of the MambisaTM vaccine induces high levels of specific IgG. The serum and mucosal antibodies show RBD-ACE2 binding inhibition capacity and neutralization activity. Conclusion Nasal immunization exhibits advantages in inducing immunity at the level of the nasopharyngeal mucosa in addition to the systemic response.

Cuban Vaccines Abdala and Mambisa against Covid-19

Intro: With the first case of COVID-19 in Cuba on March 11, 2020, the Center for Genetic Engineering and Biotechnology in Havana began an extensive vaccine program. Two vaccines based on RBD recombinant protein were developed, one for systemic administration "Abdala" and one mucosal vaccine "Mambisa". Abdala received the EUA in July 2021 and "Mambisa" completed its clinical development as a booster dose for convalescent subjects. Method(s): Two doses (25 and 50 microg) and two schedules (0-14-28 and 1-28-56 days) were evaluated in phase I clinical trials with volunteers 19 to 54 years old. The phase II and III clinical trials were also double-blind, randomized, and placebo-controlled, and included respectively 660 and 48,000 volunteers from 19 to 80 years. The anti-RBD titers were evaluated using a quantitative ELISA system developed at the Center for Immunoassay, Havana Cuba, and ELECSYS system from Roche. The RBD to ACE2 plate-based binding competitive ELISA was performed to determine the inhibitory activity of the anti-RBD polyclonal sera on the binding of the hFc-ACE2 coated plates. The neutralization antibody titers were detected by a traditional virus microneutralization assay (MN50). Finding(s): The Abdala vaccine reached 92.28% efficacy. The epidemic was frankly under control in Cuba after the vaccine introduction having reached the highest levels of cases and mortality in July 2021 with the dominance of the Delta strain. The peak of the Omicron wave, unlike other countries, did not reach half of the cases of the Delta wave with a significant reduction in mortality. The mucosal vaccine candidate "Mambisa" completed its clinical development as a booster dose for convalescent subjects reaching the trial end-point. Conclusion(s): Vaccine composition based on RBD recombinant antigen alone is sufficient to achieve high vaccine efficacy comparable to mRNA and live vaccine platforms. The vaccine also protects against different viral variants including Delta and Omicron strains.Copyright © 2023

Identifying gaps and redesigning asthma care pathway in Primary Care with multidisciplinary teams

1. Introduction: Asthma causes significant morbidity and mortality worldwide. COVID-19 scenario has revealed lacks in the current model of asthma management in Primary Care (PC). 2. Aims and objectives: The aim was to build a reference framework and address patients' needs to help asthma management improvement in a COVID-19 scenario. 3. Method(s): A scientific committee from the Spanish Respiratory Group in PC (GRAP) defined an evidence-based gold standard model for asthma care pathway including: suspected asthma, confirmed asthma, asthma follow-up, asthma exacerbations and special situations in asthma. Multidisciplinary teams (family doctors, PC nurses, practice clerks, and community pharmacists) were recruited from 17 PC settings in 7 Spanish regions to characterise their local asthma care pathway and to identify room for improvement in different areas according to previously defined gold-standards. A national online Digital Innovation Laboratory was held with representatives of the local teams to prioritise areas of improvement in terms of clinical impact and to co-design action plans. 4. Result(s): 43 to-be-improved areas in asthma care pathways were identified, classified into different categories. Continuing care, collaborative work between Primary and Secondary care, availability of qualified healthcare staff, data recording and management, digital transformation and patient empowerment were some of the areas to prioritize. 5. Conclusion(s): Multidisciplinary pre-structured team work with Digital Innovation Laboratory support could help to redesign the asthma patient's pathway and to improve the effective asthma management in a COVID-19 scenario.

In bed hybrid tracheostomy procedure in COVID-19 patients. Technique and results

Background: COVID-19 pandemic, results in a great number of critically ill patients requiring long-lasting periods of invasive mechanical ventilatory support;tracheostomy is considered during their hospital stay, to free patients from ventilatory support and optimize the resources, we developed a safe in bed hybrid tracheostomy procedure to avoid the operating room and minimize SARS-CoV2 transmission due to aerosols exposure. Method(s): We developed this protocol using PDCA (Plan, Do, Check, Act) in order to perform a safe in bed hybrid tracheostomy: percutaneous tracheostomy + flexible bronchoscopy. We used the Ciaglia Blue Rhino technique and flexible bronchoscopy. We analyzed: Gender, age, body mass index, intubation days, ventilatory parameters, procedure time, apnea time, oxygen saturation, complications and patient clinical evolution. Statistical evaluation: Fisher test, U Mann-Whitney, T test, logistic regression and Kaplan-Meier curves. Result(s): From march 2020 to February 2021, 292 patients underwent hybrid tracheostomy;Tracheostomy was successfully completed in all patients: 211 men (72.2%);81 women (27.8%), age 58.5 years old, intubation days before tracheostomy 23 days (19 to 28 days), 133 patients (45.5%) deaths due to COVID19 complications. Procedure time 6 to 14 minutes (mean 9 minutes), apnea time 147 to 360 seconds (mean 240 seconds), O2 saturation 66%-96% (mean 87%), PaO2/fiO2 106-194 (mean 142), SOFA 4-6 (mean 5). No complications due to the trachesotomy. Conclusion(s): In bed hybrid tracheostomy procedure implementation with the PDCA cycles is safe, with good results, zero procedure complications and a good and rapid learning curve.

Trends in the parents' intention to vaccinate their children against COVID-19: A comparative study in Peru

Background. Although COVID-19 vaccination has shown to be clearly beneficial in children and adolescents to reduce hospitalization and potentially transmission, there is still a lot of hesitation among parents due to concerns about vaccine safety and efficacy, especially in children under 12 years of age. Methods. We conducted a comparative study in Peru to evaluate the trends in parents' intention to vaccinate their children under 12 years of age against COVID-19, for which an online survey was administered. The survey was distributed through social networks (Facebook, Twitter, etc.), and was applied during two periods: 11/25/2021 to 12/06/2022 (Period 1) and 01/16/2022 to 01/24/2022 (Period 2). We also assessed the factors associated with the intention to vaccinate in each period through crude (cPR) and adjusted prevalence rates (aPR). Results. During period 1, there were 673 participants (69.7% women). In period 2, we had 1139 respondents (77.7% women). Regarding intention to vaccinate, 83.5% of parents intended to vaccinate their children under 12 years of age during period 1. This percentage was almost the same during period 2 (83.3%). During period 1, the factors associated with a decrease in this intention were to believe that the vaccine was not necessary (aPR 0.65;95% CI 0.44 - 0.94, p=0.022), that it would not protect (aPR: 0.14;95% CI 0.03 - 0.63, p=0.011), that it would not be safe (aPR: 0.80;95% CI 0.70 - 0.92, p=0.001), that it could cause long-termside effects (aPR: 0.92;95% CI 0.85 - 1.00, p=0.037), and to think it should not be mandatory (aPR: 0.89;95% CI 0.80-0.99, p=0.038). During period 2, besides the factors identified in period 1, not knowing about COVID-19 infection risk in children (aPR: 0.92;95% CI 0.85-1.00, p=0.042) was also associated with a decrease in the intention. Living on the highlands or jungle was associated with an increase in the intention in both periods. Conclusion. A high rate of intention to vaccinate children under 12 years of age was noted among parents in Peru, which was maintained until the end of January of 2022, right before COVID-19 vaccination started for this age group. There was a perception in some parents that the vaccine might not be necessary or safe, leading to a lower intention to vaccinate their children.

DIFFERENCES between the FIRST and the SECOND WAVE of SARS-COV-2 INFECTION in PATIENTS with IMMUNE-MEDIATED INFLAMMATORY DISEASES in ARGENTINA: DATA from the SAR-COVID REGISTRY

Background: In Argentina we have witnessed two COVID 19 waves between 2020 and 2021. The frst wave occurred during the spring of 2020 and it was related to the wild type of the virus, the second occurred during the fall/winter of 2021 when the gamma variant showed a clear predominance. During the frst wave, patient with rheumatic diseases showed a higher frequency of hospitaliza-tion and mortality (4% vs 0.26%) when compared to the general population1;at that time, however, vaccination was not yet available. Objectives: To compare sociodemographic and disease characteristics, course and outcomes of SARS-CoV-2 infection in patients with immune-mediated/auto-infammatory diseases (IMADs) during the frst and second waves in Argentina. Methods: SAR-COVID is a national, multicenter, longitudinal and observational registry, in which patients ≥18 years of age, with a diagnosis of a rheumatic disease who had confrmed SARS-CoV-2 infection (RT-PCR or positive serol-ogy) were consecutively included since August 2020. For the purpose of this report, only patients with IMADs who had SARS-CoV-2 infection during the frst wave (defned as cases occurred between March 2020 and March 2021) and the second wave (cases occurred between April and August 2021) were examined. Sociodemographic characteristics, disease diagnosis and activity, comorbidities, immunosuppressive treatment and COVID 19 clinical characteristics, complications and outcomes: hospitalization, intensive care unit (ICU) admission, use of mechanical ventilation and death were compared among groups. Descriptive statistical analysis was performed. Variables were compared with Chi squared test and Student T test or Mann Whitney test. Multivariable logistic regression models with forward and backward selection method, using hospitalization, ICU admission and death as dependent variables were carried out. Results: A total of 1777 patients were included, 1342 from the frst wave and 435 of the second one. Patients had a mean (SD) age of 50.7 (14.2) years and 81% were female. Both groups of patients were similar in terms of socio-de-mographic features, disease diagnosis, disease activity, the use of glucocorti-coids ≥ 10 mg/day and the immunosuppressive drugs (Table 1 below). Patients infected during the frst wave have higher frequency of comorbidities (49% vs 41%;p= 0.004). Hospitalizations due to COVID 19 (31% vs 20%;p <0.001) and ICU admissions (9% vs 5%;p= 0.009) were higher during the frst wave. No differences in the use of mechanical ventilation (16% vs 16%;p= 0.97) nor in the mortality rate (5% vs 4%;p= 0.41) were observed. In the multivariable analysis, after adjusting for demographics, clinical features and immunosup-pressive treatment, patients infected during the second wave were 40% less likely to be hospitalized (OR= 0.6, IC95% 0.4-0.8) and to be admitted to the ICU (OR= 0.6, IC95% 0.3-0.9). Conclusion: The impact of COVID 19 in Argentina, in terms of mortality in patients with IMADs was still higher compared to the general population during the second wave. However, the frequency of hospitalizations and ICU admissions was lower. These fndings could be explained by the introduction of the SARS COV 2 vaccination and, probably, by the cumulative knowledge and management improvement of this infection among physicians.

IS PSORIATIC ARTHRITIS A RISK FACTOR for SEVERE COVID-19 INFECTION? DATA from the ARGENTINIAN REGISTRY SAR-COVID

Background: Comorbidities, particularly cardio-metabolic disorders, are highly prevalent in patients with psoriatic arthritis (PsA) and they were associated with an increased risk of atherosclerotic cardiovascular disease, which have been associated with higher morbidity and mortality. Whether PsA enhances the risk of SARS-CoV-2 infection or affects the disease outcome remains to be ascertained. Objectives: To describe the sociodemographic, clinical and treatment characteristics of patients with PsA with confrmed SARS-CoV-2 infection from the SAR-COVID registry and to identify the variables associated with poor COVID-19 outcomes, comparing them with those with rheumatoid arthritis (RA). Methods: Cross-sectional observational study including patients ≥18 years old, with diagnosis of PsA (CASPAR criteria) and RA (ACR/EULAR 2010 criteria), who had confrmed SARS-CoV-2 infection (RT-PCR or serology) from the SAR-COVID registry. Recruitment period was between August 13, 2020 and July 31, 2021. Sociodemographic variables, comorbidities, and treatments were analyzed. To assess the severity of the infection, the ordinal scale of the National Institute of Allergy and Infectious Diseases (NIAID)1 was used, and it was considered that a patient met the primary outcome, if they presented criteria of categories 5 or higher on the severity scale. For this analysis, Chi2 test, Fisher's test, Student's test or Wilcoxon test, and binomial logistic regression using NIAID>=5 as dependent variable were performed. Results: A total of 129 PsA patients and 808 with RA were included. Clinical characteristics are shown in Table 1. Regarding PsA treatment, 12.4% of PsA were receiving IL-17 inhibitors, 5.4% IL12-23 inhibitors, one patient apremilast and one abatacept. The frequency of NIAID≥5 was comparable between groups (PsA 19.5% vs RA 20.1%;p=0.976). (Figure 1). PsA patients with NIAID≥5 in comparison with NIAID<5 were older (58.6±11.4 vs 50±12.5;p=0.002), had more frequently hypertension (52.2% vs 23%;p=0.011) and dyslipidemia (39.1% vs 15%;p=0.017). In the multivariate analysis, age (OR 1.06;95% CI 1.02-1.11) was associated with a worse outcome of the COVID-19 (NIAID≥5) in patients with PsA, while those who received methotrexate (OR 0.34;95% CI 0.11-0.92) and biological DMARDs (OR 0.28;95% CI 0.09-0.78) had a better outcome. Conclusion: Although PsA patients have a higher frequency of cardiovascular and metabolic comorbidities than those with RA, the COVID-19 severity was similar. Most of the patients had mild SARS-CoV-2 infection and a low death rate.

The Spanish Society of Clinical, Family and Community Pharmacy position statement on telepharmacy: telepharmaceutical care (TPC)

The new information and communication technologies (ICT) have been evolving for many years, but the COVID-19 pandemic has accelerated the digital transformation of society. In the healthcare field, new activities have emerged and terms such as telemedicine, telecare and teleconsultation are becoming common. They are undoubtedly a step forward, but they risk dehumanizing the contact between healthcare providers and patients. In the pharmacy-field, Telepharmacy has emerged with undeniable logistical and commercial connotations. The preferred term of the Spanish Society of Clinical, Family and Community Pharmacy is Telepharmaceutical care (TPC) which defines it as the practice of Pharmaceutical Care using ICT in order to complement the face-to face required by the patient. TPC includes the remote provision of some community pharmacy services (CPS). TPC should help the community pharmacist to provide CPS, thus improving clinical pharmaceutical practice without the dehumanizing effects that the indiscriminate application of ICT can have.

DID THE STROKE CODE IN MADRID JAM DURING THE FIRST WAVE OF COVID-19?

Background and aims: Madrid was one of the epicentres of the COVID-19 pandemic in Spain. The entire healthcare system was severely affected by the first wave of the pandemic. We aimed to assess the extent to which the acute stroke care chain was impacted. Methods: Using the stroke code (SC) cohort of SUMMA 112 (the main emergency medical service in the region), we compared all patients in the first wave of the pandemic and in the same period of the previous year. Subsequently, we collected all anonymized records from the main hospital administrative database (minimum basic data set at hospital discharge). We used ambulance response times, concordance between pre-hospital and hospital diagnosis, hospital times, and mortality to evaluate the SC protocol. The study was approved by the Ethics Committee of the Community of Madrid. Results: 966 SC were analysed (514 pre-pandemic and 452 during the first wave). Pre-hospital attention times were longer (39 vs. 35 minutes), patients stayed longer in the emergency room before admission (7.5 vs. 6.1 hours), the concordance between pre-hospital and in-hospital diagnostic suspicion did not change significantly (86% vs. 89%) and mortality decreased (9% vs 13%) during the first wave of the pandemic Conclusions: During the first wave of the pandemic, there were delays in care, especially in the on-scene time. Improvements in training might have prevented it. The high qualification of pre-hospital teams enabled them to maintain their diagnostic accuracy. The reduction in mortality needs further exploration.

REMOVED: Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database.

 : This article has been removed: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the authors. The abstract was presented as a poster in the IMED last year. Our study was about the association of Ivermectin with reduction in mortality in COVID, a retrospective study with many limitations (which is innate in these types of studies). As in any retrospective study, we could not control for all the confounding variables, mainly severity of disease in patients treated with either ivermectin or remdesivir. Another important caveat is that it was conducted in July 2021, eight months ago, when we did not have all the clinical evidence we have right now about ivermectin in COVID-19. We were very clear in the abstract conclusions that our results are only showing an "association", they are not definitive, and further randomized clinical trials must be done to prove the efficacy of Ivermectin. However, the study has been misinterpreted by a significant number of people in the scientific community and the general population, stating that based on our study, ivermectin is effective to reduce COVID-19 mortality. We are really concerned about this problem because the patients may start taking or demanding this medication from their physicians, which can potentially be harmful. We know that a retrospective study like ours cannot be used to change or guide clinical practice. Retrospective studies are only helpful to formulate hypothesis that can be utilized to design clinical trials. This misrepresentation of the study may lead to a huge public health problem, since Ivermectin is a medication that is not FDA approved for COVID treatment, and currently has proven to be ineffective in clinical trials, which are truly the gold standard to evaluate the efficacy of a medication.

Impact of Covid-19 on Infectious Disease Fellows in the United States: A National Survey to Identify Targets for Intervention

Background. The Coronavirus disease of 2019 (COVID-19) global health crisis has resulted in an unprecedented strain on healthcare systems, reorganization of medical training programs and disruption in professional and personal lives of medical trainees. The impact of COVID-19 on infectious disease (ID) fellows, who are frontline healthcare professionals, has not been assessed. Methods. We conducted a national survey of adult and pediatric ID fellows to assess impact on educational activities, availability of personal protective equipment (PPE), well-being, and career prospects. Anxiety and burnout were assessed by 7-item generalized anxiety disorder scale and abbreviated Maslach burnout inventory respectively. Invitations to participate in the survey were sent via email to all ID fellows through Accreditation Council for Graduate Medical Education (ACGME) fellowship directors. Survey responses collected from August 1 to September 30, 2020 have been reported. Results. 136 fellows completed the survey (Table 1). 84% reported their institution had provided evidence-based didactics for management of COVID-19 and 53% indicated their general ID didactics were affected by the pandemic. 86% of fellows were involved in care of patients with COVID-19, and 31% reported a shortage of PPE affecting their clinical duties. Those living in highly impacted states (CA, FL, NY, TX) at the time of the survey were 1.70 times as likely to experience moderate to severe anxiety (vs. minimal to moderate) than those in other states;similarly, those who saw ≥11 COVID-19 patients weekly and reported PPE shortages were 2.5 and 2.0 times as likely, respectively, to experience moderate to severe anxiety compared to their peers who took care of 10 or fewer COVID-19 patients and did not experience PPE shortages. Burnout scores were not significant (Table 2). Conclusion. It is imperative that ID fellows feel adequately protected and supported during this pandemic. Pandemic preparedness should be included in the ID fellowship curriculum. Interventions for anxiety and burnout reduction should be implemented. ID fellowship programs should continue to accept feedback from fellows to ensure their ongoing safety, well-being, and education as we navigate this pandemic.

SARS-CoV-2 Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians

Background. Peru started its national vaccination campaign in February 2021 using Sinopharm vaccine, targeting healthcare personnel on its initial phase. Although the immunogenicity of this vaccine was tested in clinical trials, there are no studies that evaluated the humoral response post vaccination in Peru. Methods. We conducted a cross sectional study, which objective was to evaluate the humoral immunogenicity triggered by the Sinopharm vaccine in Peruvian physicians. We collected demographic and epidemiologic data via an electronic. The SARS-CoV-2 spike protein S1/S2 antibodies were measured by chemiluminescense (Liaison®). A positive test was defined as >15 U/ml, which has correlation of 95% with neutralizing antibodies measured by plaque reduction neutralizing test. Results. 92 participants were enrolled in the study. The epidemiologic characteristics are described in table 1. The mean level of antibodies measured at least 2 weeks from the second vaccine dose was 67.5 ± 70.5 U/ml. 85.7% of the study cohort had positive S1/S2 antibodies. In the univariate analysis, an imperfect negative correlation was found between the level of antibodies and participants' age (r= -0.24;regression F test 5.25;p = 0.0242). A weak negative correlation was observed between the antibody titer and the time elapsed from the second vaccine dose and the day of antibody measurement (r= -0.17). A higher antibody level post vaccine was found in individuals who worked in COVID units (105.5 U / mL vs 58.2 U / mL;p = 0.0125), and in participants with history of COVID (216.5 U / mL vs 81.2 U / mL;p = < 0.0000). Hypertension was associated with lower antibody titers (36.9 U / mL vs. 74.6;p = 0.0464). In the multivariate analysis, working in COVID units, having previous COVID infection and shorter time from second vaccine dose and day of antibody measurement were associated with higher antibody levels post vaccine (table 2). Conclusion. Our study showed that the time elapsed from the second vaccine dose and the day of antibody measurement, having previous COVID-19 infection and working in COVID -19 units may help to predict higher antibody titers post vaccine. Larger studies to evaluate the humoral response post Sinopharm vaccine and its clinical implications are still needed in Peru.

[Adaptation of surgery practice during the Covid-19 pandemic. Ureteroscopy in outpatient surgery.]

OBJECTIVE: The World Health Organizationdeclared a pandemic status due to the COVID-19 disease caused by the new coronavirus SARS-Cov-2 in March 2020. This caused high health pressure that hashad an impact on the Spanish National Health System and Granada has been one of the most affected provincesnationwide. The high healthcare pressure derived from it has had an impact on the National Health System throughout the Spanish territory, with Granada beingone of the most affected provinces nation wide. The increase in the admissions of patients with COVID-19 in such a short time has forced us to optimize hospital resources, prioritizing them in patients with COVID-19 and oncological or urgent pathology. In this context, the increasingly frequent and recurrent lithiasis is treated conservatively. However, the prolongation of the pandemic situation poses the challenge of offering definitive treatment to these patients. MATERIAL AND METHODS: We present the rearrangement performed in our Lithotripsy Unit with the aim of developing a comprehensive and alternative protocol for performing ureteroscopies on an outpatient basis, assuming the patient from admission to hospital discharge, with the collaboration of the Anesthesiology service. RESULTS: In this new protocol, 35 ureteroscopies were performed without noticing intraoperative complications or during the recovery period developed in the Day Hospital integrated within the Lithotripsy Unit. CONCLUSIONS: The redistribution of our resources has allowed us to continue performing ureterorenoscopies on an outpatient basis without the need to use hospital beds and reducing the traffic of patients within the hospital itself with an adequate safety profile.

Sectorial and regional differences of the economic recession caused by the COVID-19 pandemic in Mexico and public policy measures to face it

Based on the extraordinary provisions implemented in Mexico by the federal government to reduce the spread of infections caused by the COVID-19 pandemic, productive activities considered non-essential were interrupted, leading to the contraction of the economy. Several agencies have estimated the magnitude of this recessive trend through aggregated indicators at national level;however, little is known about how this process affected inner areas of the country. Spatial areas at subnational scale, such as regions, states, or municipalities, showed differential effects because their productive structures and other internal and external factors regulated the degree to which economic sectors were affected. To alleviate the adversity caused by this situation, state governments took various actions. The differential behavior of economic recession in states and the scope of government actions are indicators of vulnerability levels and institutional responsiveness of the territorial areas studied. This work has a dual objective: On the one hand, estimate the differential performance of the economic activity recorded by states in Mexico over the period of highest social lockdown and restrictions imposed on business operations during the pandemic. The aim is to measure the relative losses of Gross Domestic Product (GDP) of productive sectors and explain the causes of economic and regional recessive behavior. Second, it analyzes the actions taken by state governments to mitigate the effects of economic inactivity, especially those related to the temporary closure of businesses and job losses, and the impact on vulnerable social groups. A methodological technique was used to estimate the sectoral losses of GDP at state level by determining the extent of the impact to economic activities deemed "non-essential" and considering the period of greatest restriction on business operations during the second quarter of 2020. To assess public policies issued to face the critical period, we identified economic actions implemented by the 32 state governments as recorded by the National Commission for Regulatory Improvement for the period analyzed. After arranging them according to modality in each case, specific actions were analyzed, allowing to illustrate the nature of supports and their scope by identifying the economic segments and social sectors addressed. The results of this work reveal that the poor performance of productive sectors at state level was not only associated with the suspension of non-essential activities;factors such as specialized productive structures, activities involving a large proportion of on-site work or on-site consumption of goods and services, as well as integration into global value chains, were also key to explaining this recessive behavior. In this regard, our results are consistent with similar analyses reported from studies conducted in other countries that used similar and other measurement approaches. The drop in sectoral GDP in the Mexican states was consistent with the productive profile of the units analyzed;in other cases, the economic recession was distributed according to regional patterns. States with tourism as a major economic activity, such as Quintana Roo and Baja California Sur, showed the greatest drop in GDP. Also highly affected were states hosting businesses linked to international value chains, such as the automotive and electronics industries, a phenomenon that occurred mainly in the central western and northern regions of the country. The states that were worst at facing the recession were those dedicated to primary and industrial food production. This condition was observed in Sinaloa and Colima, while Chiapas and Oaxaca stood out in the southern region of the country. Actions taken by state governments focused on micro and small companies, the unemployed, and the most vulnerable persons. Although the importance of institutional transfers and incentives to face the economic emergency is not discredited, these initiatives had a buffering rather than reactivating effect. This is e plained by the targeting of the actions taken, the financial constraints of the states, and the temporary nature of the supports. The economic fragility of most state economies and the extent of government actions to face the recession revealed the need for risk-prevention strategies to effectively address pandemic events. © 2021 Instituto de Geografia. All rights reserved.

Prevalence and risk-factors of COVID-19 in pregnancy: Living systematic review and metaanalysis

Background Since the first report of COVID-19 in December 2019, there have been significant concerns regarding the effects of the disease on pregnant and recently pregnant women. Quantifying prevalence, and identifying risk factors for severe COVID-19 in this population is key to planning and providing effective clinical maternal care. Objectives To identify rates of COVID-19 amongst pregnant and recently pregnant women and to identify maternal risk factors for severe COVID-19 and worsening clinical outcomes. Design To address the objectives using the developing evidence base we are using a 'Living systematic review' study design. Methods A systematic search of various databases and sources was conducted, including: Medline, Embase, Cochrane database, WHO COVID-19 database, CNKI, Wanfang databases, preprint servers, social media, reference lists of guidelines and included studies until the 6th of October 2020. Quality assessment of prevalence studies was done using the risk of bias tool by Hoy et al. and comparative cohorts using the Newcastle Ottawa Scale. Data extraction was completed with a pre-piloted form by two independent reviewers. The analysis is undertaken monthly and findings are regularly updated. Results are disseminated through our website: https://www.birmingham.ac.uk/research/who-collabora ting-centre/pregcov/index.aspx. The living systematic review process and collated database has given rise to distinct review questions, and the authors of this focused on prevalence and maternal risk factors. Random effects meta-analysis was used to determine prevalence of COVID-19 and the maternal risk factors associated with severe COVID-19. Results 192 studies were included. Overall, 10% (95% confidence interval 7% to 12%;73 studies, 67 271 women) of pregnant and recently pregnant women attending or admitted to hospital for any reason were diagnosed as having suspected or confirmed COVID-19. Increased maternal age (1.82, 1.27 to 2.63;I2 = 30.1%;7 studies;3561 women), high body mass index (2.37, 1.83 to 3.07;I2 = 0%;6 studies;3380 women), pre-existing maternal comorbidity (1.81, 1.49 to 2.20;I2 = 0%;3 studies;2634 women), chronic hypertension (2.0, 1.14 to 3.48;I2 = 0%;2 studies;858 women), pre-existing diabetes (2.12, 1.62 to 2.78;I2 = 0%;3 studies;3333 women), and pre-eclampsia (4.21, 1.26 to 14.0;I2 = 0%;4 studies;274 women) were associated with severe COVID-19 in pregnancy. Conclusions 1 in 10 pregnant or recently pregnant women attending or admitted to hospital are estimated to have COVID-19. Pre-existing co-morbidities, chronic hypertension, pre-eclampsia, pre-existing diabetes, high maternal age, and high BMI are risk factors for severe COVID-19.